[ad_1]
A man wearing a mask walks past an Nvidia logo in Taipei, Taiwan.
Soba photos | Light Rocket | Getty Images
Chip maker nvidia It will invest $50 million in Recursive pharmacology To accelerate the development of biotechnology company artificial intelligence models For discovery drugs, the companies said Wednesday.
Recursion stock rose 80% after the announcement. Shares of Nvidia, which helped fuel stock market gains this year on hopes for artificial intelligence computing chips, rose more than 2%.
Recursion uses AI-powered models to identify and design new therapies, and offers those models to other drug makers, including Roach And Bayer.
Recursion, a Salt Lake City, Utah-based company, will use its more than 23,000 terabytes of biological and chemical datasets to train its AI models on the Nvidia cloud platform. AI models typically require massive amounts of data, usually measured in terabytes, to train.
Nvidia could then license these AI models on BioNeMo, the company’s cloud service for generative AI in drug discovery that was introduced earlier this year.
Recursion expects to use BioNeMo to support its internal drug pipeline and those of its current and future partners. Recursion is conducting human trials of five of its drugs.
“Our collaboration with NVIDIA represents two best-in-class companies coming together to help solve one of the world’s toughest challenges, drug discovery,” said Recursion CEO Chris Gibson in the release.
Nvidia’s investment is the latest example of the AI ​​craze making its way into the pharmaceutical industry. Drug makers are increasingly recognizing the potential of AI to bring life-saving treatments to people faster.
accident In April, it said it would harness the power of artificial intelligence to develop the company’s RNA technology, which is used in Covid vaccines. a month later, Google Cloud has launched two new AI tools aimed at helping biotechnology and pharmaceutical companies accelerate drug discovery.
Nvidia, which produces chips used to power artificial intelligence, is seen as a big winner in the AI ​​boom.
The company reached a market value of $1 trillion for the first time in June, as part of a more than 200% increase in share price since the beginning of this year on the back of huge demand for artificial intelligence.
The investment in Recursion only deepens Nvidia’s bet in popular technology.
The announcement also comes as Recursion ramps up its focus on artificial intelligence. company in May acquired two companies in AI-driven drug discovery for $87.5 million.
Other AI-powered drugmakers also traded higher on Wednesday after the announcement.
knowledge increased by up to 12%, while AbCellera Biology It jumped more than 13%.
— CNBC’s Benjamin Taubman contributed to this report.
[ad_2]
